Blog / tracking
SS-31 Research Explained: What Elamipretide Studies Show and What to Track
What human trials of SS-31 (elamipretide) report, what the 2025 FDA decision means, and what to keep in your peptide tracker.
By Peppy Team6 min read
SS-31 is one of the peptides people ask about most when the conversation turns to mitochondria and energy. You may also see it called elamipretide, and since 2025 it has a brand name, Forzinity. That makes it unusual. Many peptides discussed online have only early research behind them. SS-31 has gone through human trials, including one that failed and one that led to an FDA decision.
This post walks through what the research actually reports, where it falls short, and what is worth keeping in your peptide tracker if a licensed provider has you on it. It is an explainer, not advice. Whether any peptide fits your situation is a decision for your provider.
What SS-31 is
SS-31 is a small synthetic peptide built from four amino acids. It was designed to reach the inner membrane of mitochondria, the parts of cells that produce energy.
The FDA describes it this way: the drug works by binding to the inner part of the mitochondria, improving mitochondrial structure and function. The specific target is a fat molecule in that membrane called cardiolipin. Researchers think that when cardiolipin is damaged or abnormal, mitochondria work less efficiently. SS-31 was developed to help stabilize it.
The names you will see
- SS-31: the original research name, still common in papers and online discussion.
- Elamipretide: the generic drug name used in clinical trials.
- Forzinity: the brand name of the FDA approved product.
If you keep records, it helps to note which name your provider or pharmacy uses, so your log matches your prescription paperwork.
What the research shows
The human evidence for SS-31 comes mainly from two rare genetic conditions. The results in each were quite different, which is a useful reminder that a peptide can look promising in one group and not in another.
Barth syndrome and the TAZPOWER trial
Barth syndrome is a rare, serious inherited disease of the mitochondria. It mostly affects boys and men and can involve heart problems, muscle weakness and fatigue.
TAZPOWER started as a 28 week randomized, placebo controlled trial and then continued as an open label extension, where everyone received the drug. A 2024 paper in Genetics in Medicine reported the long term results. Ten patients entered the extension and eight reached the 168 week visit.
The authors reported:
- The peptide was generally well tolerated, and injection site reactions were the most common side effect.
- Distance on the six minute walk test improved from the start of the extension at every time point measured.
- Fatigue scores stayed better than baseline throughout.
- Some heart measurements and a lab marker linked to cardiolipin showed improvement trends.
These are encouraging findings, but the group was very small and the extension was not blinded, which limits how much weight they carry.
The FDA decision in 2025
In September 2025 the FDA granted accelerated approval to Forzinity as the first treatment for Barth syndrome, in patients weighing at least 30 kg.
Accelerated approval is a specific pathway. It lets the FDA approve a drug for a serious condition based on a measure that is reasonably likely to predict benefit, rather than proof of the benefit itself. In this case the measure was improved strength in the muscle that straightens the leg at the knee.
The FDA is requiring a new randomized, double blind, placebo controlled trial to confirm that this strength gain translates into real benefits, such as standing more easily or walking farther. If that confirmation does not come, approval under this pathway can be withdrawn.
Mitochondrial myopathy and the MMPOWER-3 trial
The second major line of research tested SS-31 in primary mitochondrial myopathy, a group of genetic disorders that weaken muscles and reduce exercise capacity.
MMPOWER-3, published in Neurology in 2023, was a larger phase 3 trial. It randomized 218 adults to the peptide or placebo for 24 weeks.
The trial did not meet its main goals. There was no meaningful difference between groups in the six minute walk test or in fatigue scores. The authors did report that the peptide was well tolerated, with most side effects mild to moderate.
What the two lines of evidence mean together
Put side by side, the research tells a measured story:
- In Barth syndrome, a small group showed improvements, and the FDA judged the evidence enough for a conditional approval.
- In a broader mitochondrial muscle disease, a larger and stronger trial found no benefit on its main measures.
- The approved use is narrow. It covers one rare condition, and it still needs confirmation.
So claims online that SS-31 boosts energy, slows aging or improves performance in healthy people go well beyond what these trials tested. Research findings also vary from person to person, and only a licensed provider can judge whether any of it applies to you.
What to track if your provider has you on SS-31
If a provider has prescribed or is supervising SS-31 for you, a simple, steady record makes appointments far more useful.
Doses, timing and missed doses
Log each dose your provider gave you, with the date and time. Note any missed dose and what you did about it, based on what your provider told you.
Injection sites and skin reactions
Because injection site reactions were the most commonly reported side effect in the trials, they are worth recording. Note the site you used and any redness, itching, swelling or soreness, with a rough severity. Rotating sites and keeping a record of where you injected makes patterns easier to spot.
Function, not just feelings
The trials measured things like walking distance, muscle strength and fatigue. Keep plain notes your provider can compare over time:
- How far or how long you walked on a normal day
- Whether stairs or standing up felt easier, harder or the same
- A simple daily energy or fatigue rating
Vial details
Record the vial strength, the date you opened or mixed it, and roughly how many doses are left. If your vial needs mixing, the amount of water used matters for working out the volume to draw. The free peptide calculator lets you enter the vial strength, the water you added and the dose your provider gave you, then shows the units to draw on your syringe. It is a tool for the arithmetic, not a source of dosing decisions.
Keeping a record in Peppy
Peppy is a peptide tracker app for iPhone, and SS-31 is part of its peptide library. You enter the vial strength, any water mixed and the dose your provider gave you, and the app shows that dose in units on your syringe.
From there you can set dose reminders, log each dose to build a dose history you can show at appointments, and use the injection site rotation body map to see which sites have rested. The vial tracker keeps count of what is left. Side effect check-ins sit next to your doses, so a skin reaction or a change in energy lines up with the dates it happened. Everything stays on your iPhone and your own iCloud backup.
Questions to bring to your provider
If SS-31 has come up in your care, these are reasonable questions to ask:
- What is the goal of this treatment for me, and how will we know if it is working?
- Which measurements should I track at home between visits?
- What should I do if I miss a dose?
- Which injection site reactions are expected, and which should I report right away?
The bottom line
SS-31 is a mitochondria targeting peptide with real human research behind it, but the results are mixed. It earned a conditional FDA approval for Barth syndrome based on a small study and a muscle strength measure, while a larger trial in mitochondrial myopathy did not show benefit. Claims beyond those settings are not supported by these trials.
If you use it under a provider's care, a consistent log of doses, sites, side effects and daily function gives your provider the clearest picture of how it is going for you.
More from the blog

dose log6 min read
BPC-157 Tracker: Logging Injections, Sites and How You Feel
A practical guide to using a BPC-157 tracker: what to log at every injection, how to keep vial math straight and how to record sites and symptoms.
- dose log
- injection sites
- vials

tracking6 min read
TB-500 Research Explained: What Studies Show and What to Track
What TB-500 and thymosin beta-4 studies actually show, where evidence is thin, and what a peptide tracker should record with your provider.
- tracking
- dose log
- side effects

tracking6 min read
BPC-157 Research Explained: What Studies Show and What to Track
What animal and human studies on BPC-157 actually show, how to read bold claims, and what a peptide tracker should record if your provider uses it.
- tracking
- dose log
- side effects
